Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics is executing a methodical and strategic approach in employing their manufacturing and production expertise to develop and commercialize their leading cell therapy candidate COR1, while utilizing the experience gained from developing other candidates like OpRegen. Their proprietary AlloSCOPE platform, quality assurance assays, and TAI formulation set them apart as a leader in the biotech industry. Upcoming catalysts, such as the Phase 2a GAlette study and updates from collaborations with Roche and Genentech, are expected to further drive the company's growth and success. However, as with any biotech company, there are inherent risks in clinical development, regulatory approvals, partnerships, legal issues, and market competition.

Bears say

Lineage Cell Therapeutics is facing financial struggles as their Q4 2025 revenue was a low $6.6M compared to their operating expenses of $13.2M, resulting in a -$6.5M loss. Although they have multiple promising programs and collaborations in the pipeline, such as the OpRegen program and the William Demant Invest partnership, they may struggle to fund these initiatives with their current financial standing, leading to a potential slowdown in progress and growth. This, coupled with the lack of FDA approval for any of their programs at this time, may lead to a negative outlook on the company's stock.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.